2. Metabolic Enzyme/Protease Cell Cycle/DNA Damage Autophagy Apoptosis
  3. Cathepsin DNA/RNA Synthesis Autophagy Apoptosis
  4. GN-604

GN-604 is a targeted drug conjugate (Targeted Drug Conjugate, TDC) formed by conjugation of GNS561 (HY-137978) with DN604, a Pt (II) complex. GN-604 selectively inhibits PPT1, induces lysosomal dysfunction, suppresses autophagy and triggers apoptosis. GN-604 promotes the targeted sequestration of Pt (II) inside cells, induces DNA damage and inhibits the proliferation of malignant cells. GN-604 is applicable to research related to triple-negative breast cancer.

For research use only. We do not sell to patients.

GN-604

GN-604 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

GN-604 Related Antibodies

Top Publications Citing Use of Products

View All Cathepsin Isoform Specific Products:

View All Isoforms
Cathepsin B Cathepsin C Cathepsin D Cathepsin E Cathepsin K Cathepsin L Cathepsin S

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms
RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

GN-604 is a targeted drug conjugate (Targeted Drug Conjugate, TDC) formed by conjugation of GNS561 (HY-137978) with DN604, a Pt (II) complex. GN-604 selectively inhibits PPT1, induces lysosomal dysfunction, suppresses autophagy and triggers apoptosis. GN-604 promotes the targeted sequestration of Pt (II) inside cells, induces DNA damage and inhibits the proliferation of malignant cells. GN-604 is applicable to research related to triple-negative breast cancer[1].

In Vitro

GN-604 (72 h) inhibits proliferation of HUH-7, HepG2, HT-29, MDA-MB-231, A549, and CDDP (HY-17394)-resistant A549/CDDP cancer cells with IC50 values ranging from 5.32 μM to 9.03 μM, and shows high tumor selectivity with low toxicity to HUVEC cells (IC50 = 29.56 μM) and potential to overcome CDDP resistance[1].
GN-604 (10 μM; 24 h) inhibits MDA-MB-231 cell migration more effectively than CDDP or GNS561 alone, with a migration rate of 37.4%[1].
GN-604 (10-20 μM; 2 weeks) inhibits MDA-MB-231 cell colony formation in a dose-dependent manner, with greater efficacy at 20 μM than at 10 μM[1].
GN-604 (10-20 μM; 24 h) induces apoptosis in MDA-MB-231 cells in a dose-dependent manner, with an apoptotic rate of 15.8% at 10 μM and 33.6% at 20 μM[1].
GN-604 (10 μM; 24 h) induces S phase arrest in MDA-MB-231 cells[1].
GN-604 (10 μM; 24 h) downregulates PPT1 expression and increases LC3B-II levels in MDA-MB-231 cells, disrupting lysosomal function and inhibiting autophagic flux[1].
GN-604 (10 μM; 24 h) upregulates γ-H2AX expression in MDA-MB-231 cells, indicating induction of DNA double-strand breaks[1].
GN-604 (10 μM; 12 h) induces lysosomal dysfunction in MDA-MB-231 cells, as evidenced by increased LysoTracker Red fluorescence intensity and enlarged lysosome size[1].
GN-604 (10 μM; 12 h) disrupts lysosomal acidification in MDA-MB-231 cells, as shown by altered Acridine Orange fluorescence ratios[1].
GN-604 (0.25 μM; 12 h) achieves 1.8-fold higher intracellular platinum accumulation in MDA-MB-231 cells than CDDP at the same concentration[1].
GN-604 (10-20 μM; 12 h) induces DNA strand breaks in MDA-MB-231 cells in a dose-dependent manner, with greater damage observed at 20 μM than at 10 μM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GN-604 Related Antibodies

Cell Migration Assay[1]

Cell Line: MDA-MB-231
Concentration: 10 μM
Incubation Time: 24 h
Result: Limited MDA-MB-231 cell migration to a rate of 37.4%, which was more potent than standalone CDDP (43.6%) or GNS561 (41.2%), but slightly less potent than the GNS561+CDDP combination (28.3%).

Cell Proliferation Assay[1]

Cell Line: MDA-MB-231
Concentration: 10-20 μM
Incubation Time: 24 h, followed by ~2 weeks of drug-free incubation
Result: Inhibited colony formation in a dose-dependent manner, with efficacy equivalent to GNS561 at 10 μM and stronger inhibition at 20 μM, though slightly less potent than the GNS561+CDDP combination.

Apoptosis Analysis[1]

Cell Line: MDA-MB-231
Concentration: 10-20 μM
Incubation Time: 24 h
Result: Induced apoptosis in MDA-MB-231 cells in a concentration-dependent manner: 10 μM resulted in 15.8% apoptotic cells, which was higher than CDDP (11.8%) and GNS561 (14.9%); 20 μM resulted in 33.6% apoptotic cells, comparable to the GNS561+CDDP combination (38.6%).

Cell Cycle Analysis[1]

Cell Line: MDA-MB-231
Concentration: 10 μM
Incubation Time: 24 h
Result: Induced marked S phase arrest in MDA-MB-231 cells, increasing the proportion of cells in S phase compared to the control group.

Western Blot Analysis[1]

Cell Line: MDA-MB-231
Concentration: 10 μM
Incubation Time: 24 h
Result: Significantly reduced PPT1 expression and increased LC3B-II levels, indicating impaired autophagic flux and lysosomal dysfunction.\nUpregulated γ-H2AX expression, inducing more pronounced DNA damage than CDDP alone, though slightly less than the GNS561+CDDP combination.
In Vivo

GN-604 (14-28 mg/kg; i.v.; once a week; 24 days) exhibits dose-dependent antitumor efficacy in MDA-MB-231 xenograft mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude (female, 5 weeks old, 16-18 g)[1]
Dosage: 14.0 mg/kg; 28.0 mg/kg
Administration: i.v.; once a week; 24 days
Result: Achieved a tumor growth inhibition (TGI) rate of 63.65% at 14.0 mg/kg.
Increased the TGI rate to 72.88% at 28.0 mg/kg, which was higher than the TGI of the GNS561 + CDDP combination group.
Caused no significant body weight loss over the 24-day period.
Showed no obvious abnormalities in histopathological analysis of major organs (heart, liver, spleen, lung, kidney).
Induced pronounced morphological alterations including cellular deformation, necrosis, and nuclear fragmentation in tumor tissues at 28.0 mg/kg.
Upregulated γ-H2AX (a DNA damage marker) substantially and downregulated PPT1 expression pronouncedly in tumor tissues, with effects increasing with dose.
Molecular Weight

848.21

Formula

C31H37ClN8O6Pt
SMILES

ClC(C=C1)=CC=C1CNC2=NC3=CC=CC=C3C(N4CCC(NC(CCC(N/N=C5CC(C([O-][Pt+2]([NH3])([NH3])[O-]6)=O)(C6=O)C/5)=O)=O)CC4)=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

GN-604 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

GN-604GN604GN 604CathepsinDNA/RNA SynthesisAutophagyApoptosisHT-29PPT1A549/CDDPtriple-negative breast cancerMDA-MB-231A549Palmitoyl-protein thioesterase 1HepG2HUVECHUH-7Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
GN-604
Cat. No.:
HY-183351
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.